Shares of BioXcel Therapeutics have experienced downward pressure and significant volatility driven by standard clinical-stage biotechnology risks, including mixed trial readouts, concerns over cash burn rates, capital-raising dilution through secondary equity offerings, and the broader macroeconomic cooling trend affecting speculative small-cap healthcare equities listed on public markets.